VisioCyt® Bladder obtains temporary coverage under the RIHN 2.0 program: a major breakthrough for the non-invasive diagnosis of bladder cancer

VisioCyt® Bladder, an innovative non-invasive solution for diagnosing bladder cancer, is now covered under the national RIHN 2.0 program following a favorable joint evaluation by the French National Authority for Health (HAS) and the Directorate General for Health (DGS)